Consequently, it appears that with NGAL, similar to the use of B-type natriuretic peptide (BNP) for diagnosis of heart failure [38] and for many other biomarkers, there could exist a grey zone where the clinical judgment coupled with biomarker assessment is crucial to the prompt and accurate diagnosis of AKI [45]. The gene discussed is LCN2; the disease is acute kidney injury.